Prioritisation of COVID-19 boosters in the omicron era.

Authors:
Irving SA; Sundaram ME.

Journal:
Lancet

Publication Year: 2022

DOI:
10.1016/S0140-6736(22)01971-7

PMCID:
PMC9560778

PMID:
36244366

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Lancet

Abbreviation: Lancet

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-…
Barsosio HC; Madanitsa M; Ondieki ED and 13 more (2024) - Transparency Score: 4/6
Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled t…
Patel PD; Liang Y; Meiring JE and 20 more (2024) - Transparency Score: 4/6
A waiting crisis?
Salisbury L; Baraitser L; Catty J and 5 more (2023) - Transparency Score: 2/6
Burden of disease attributable to unsafe drinking water, sanitation, and hygiene in domestic settin…
Wolf J; Johnston RB; Ambelu A and 18 more (2023) - Transparency Score: 3/6
Defining collaborative surveillance to improve decision making for public health emergencies and be…
Archer BN; Abdelmalik P; Cognat S and 22 more (2023) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"MES has received research support from GlaxoSmithKline for respiratory syncytial virus research. SAI reports no competing interests."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025